Accueil / Communiqués / SEQENS North America Picks up Six 2019 Life Science CMO Leaderships Awards

SEQENS North America Picks up Six 2019 Life Science CMO Leaderships Awards

Monday, March 11th 2019 at 1:15pm UTC

Has now won 30 CMO Leadership Awards since 2014

NEWBURYPORT, Mass.–(BUSINESS WIRE)– SEQENS North America (formerly PCI Synthesis, Inc.), a pharmaceutical
manufacturer of new chemical entities (NCEs), generic active
pharmaceutical ingredients (APIs), and other specialty chemical
products, today announced that it has won six 2019 Life Science
Leader
 CMO Leadership Awards. The company won in every category:
Quality, Capabilities, Compatibility, Expertise, Reliability, and
Service across all three groups of respondents (Big Pharma, Small Pharma
and Overall (combined Big and Small Pharma).

This is the fifth time in the CMO Leadership Awards program’s eighth
year that SEQENS has been awarded multiple awards, including across all
six major categories. The company has now won 30 CMO Leadership Awards
since 2014. The awards will be presented at The CMO Leadership Awards
Reception at Convene, at 237 Park Avenue on March 20, 2019 in NYC.

For the 2019 CMO Leadership Awards, Life Science Leader magazine
teamed up with Industry Standard Research (ISR) to determine the award
recipients. More than 120 contract manufactures were assessed by 23
performance metrics in ISR’s annual Contract Manufacturing Quality
Benchmarking
survey. Survey participants were recruited from Pharma
and Biopharma companies of all sizes and were screened for
decision-making influence related to working with contract manufacturing
suppliers. Respondents only evaluate companies with which they have
worked on an outsourced project within the past 18 months. This level of
qualification ensures that survey responses are based on actual
involvement with contract manufacturers and clear experiential data.

“Each year, the value that CMOs bring to individual biotech and pharma
companies increases, as does the overall importance of the service
sector to our entire and global drug development and manufacturing
industry,” said Louis Garguilo, Chief Editor and Conference Chair,
Outsourced Pharma.

“Amid growing industry competition, the fact that SEQENS North America
continues to win CMO Leadership Awards, especially across all
categories, is a testament to our people, training and equipment as well
as to our results-driven culture – particularly since winners are based
on input from people who work with us,” said Ed Price, president and CEO
of SEQENS North America. “While we’re now known as SEQENS North America,
part of a global CDMO that can offer more resources and even deeper
expertise, our commitment to being responsive to our sponsors remains a
core value.”

SEQENS North America, which provides small and mid-sized companies with
the expertise to manufacture complex small molecules to be used as APIs,
has a portfolio of commercially approved products that now includes nine
commercial products that either have or are imminently receiving FDA
approval for sale in the U.S. The division has more than 17 API and
other advanced materials products in its pipeline.

About SEQENS North America
SEQENS North America (formerly
PCI Synthesis) is a Pharmaceutical Development CDMO (Contract
Development and Manufacturing Organization) based in Newburyport, Mass.,
a division of SEQENS, an integrated global leader in pharmaceutical
synthesis and specialty ingredients with 24 manufacturing sites and 3
R&D centers in Europe, North America and Asia.

SEQENS North America is also a commercial manufacturer of new chemical
entities (NCEs), generic active pharmaceutical ingredients (APIs), and
other specialty chemical products for the medical device industry. As a
CDMO, SEQENS North America provides emerging and mid-sized
pharmaceutical companies access to the expertise needed to develop and
manufacture complex small molecules. To learn more about SEQENS North
America, its proprietary NCE development activities and process R&D
capabilities please visit www.seqens.com.

Contacts

Linda Pendergast-Savage
Birnbach Communications
508-224-7905
lpendergastsavage@birnbachcom.com

Source: SEQENS North America


Voir aussi

Innovations in Artificial Intelligence, Blockchain, Quantum Computing, Robots, and Catalysts, 2019 Study – ResearchAndMarkets.com

Friday, March 22nd 2019 at 3:01pm UTC DUBLIN–(BUSINESS WIRE)– The « Innovations in Artificial Intelligence, Blockchain, …